Clinical trials in follicular lymphoma

The list below shows  The Lymphoma Group's current clinical trials open for recruitment for follicular lymphoma patients.

If you would like to know how to access our trials, please see how to contact us.

  • GEN3013 - Phase 1/2 study using antibody GEN3013 to target CD20- expressing cells in patients with B cell non-Hodgkin lymphoma

    Suitable for patients with B cell non-Hodgkin lymphoma which has come back after previous treatment
  • PETReA - A phase 3 trial testing whether PET scans can help make treatment decisions for people with follicular lymphoma

    Suitable for patients who haven't yet received any treatment

  • JNJLYM1001 - A phase 1 trial of a new treatment called JNJ-75348780 in people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia.
  • CCS1477-02 - A phase 1/2a study of CCS1477 in blood cancers, including relapsed or refractory non-Hodgkin lymphoma.
  • StepPharma/STP938 – Testing STP938 in people with T-cell and B-cell lymphomas that has relapsed or is refractory
  • MK1026-003 - A trial of MK-1026 for some types of blood cancer, including follicular lymphoma
  • REFRACT – a randomised trial of standard therapy vs new therapy experimental arms
  • NX-5948-301 – Testing NX-5948 in patients with relapsed or refractory B cell lymphoma including follicular lymphoma
  • CCS1477 – Testing CCS1477 in blood cancers, including relapsed or refractory follicular lymphoma
  • ZUMA-22 – a randomised trial of CAR-T (Axi-cel) vs standard therapy


With special thanks to the following:

Lymphoma actionCRUKBloodwiseNCRI

For further information on each trial, please visit the Find a trial page on Lymphoma Action’s website.

Last updated: October 2023